Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | APAF1 | O14727 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.43 |
| ▸ | TUBB3 | Q13509 | 6/20 | 0.43 |
| ▸ | KDR | P35968 | 5/20 | 0.43 |
| ▸ | EGFR | P00533 | 3/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.43 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.43 |
| ▸ | TUBB | P07437 | 2/20 | 0.43 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.43 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.43 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.43 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.43 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.43 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.43 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.43 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4300169 | 0.84 | KDR (0.51) | TUBB3KDREGFRPDGFRBTUBB4A | |
| SCHEMBL4300255 | 0.82 | MEN1 (0.53) | MAPTTUBB3KDREGFRPDGFRB | |
| SCHEMBL4303340 | 0.78 | POLB (0.44) | TUBB3KDREGFRPDGFRBTUBB4A | |
| SCHEMBL4310018 | 0.78 | SLC2A1 (0.41) | MAPTAPAF1LMNASENP8SENP7 | |
| SCHEMBL9877961 | 0.72 | TSHR (0.42) | MAPTL3MBTL1 | |
| SCHEMBL13780086 | 0.72 | MEN1 (0.59) | MAPTAPAF1LMNASENP8SENP7 | |
| SCHEMBL114319 | 0.70 | CA1 (0.61) | MAPTTUBB3KDREGFRPDGFRB | |
| SCHEMBL3113897 | 0.70 | EGFR (0.54) | TUBB3KDREGFRPDGFRBTUBB4A | |
| SCHEMBL3110865 | 0.70 | CSF1R (0.56) | KDREGFRPDGFRBPDGFRAMERTK | |
| SCHEMBL20111051 | 0.69 | KDR (0.47) | TUBB3KDREGFRPDGFRBTUBB4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090280133-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2009-11-12 | — | — | US | claimed |
| WO-2008061112-A9 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF | MYRIAD GENETICS INC (US) | 2008-09-18 | — | — | WO | claimed |
| WO-2008061112-A2 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF | MYRIAD GENETICS, INC. (US) | 2008-05-22 | — | — | WO | claimed |
| US-20090280133-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090280133-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090280133-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2009-11-12 | — | — | US | disclosed |
| WO-2008061112-A9 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF | MYRIAD GENETICS INC (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008061112-A9 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF | MYRIAD GENETICS INC (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008061112-A2 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF | MYRIAD GENETICS, INC. (US) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008061112-A2 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF | MYRIAD GENETICS, INC. (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090280133-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF | MKI67, CCNI, CCNA1 | MAPT 3821/4885APAF1 604/4885LMNA 2800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.